IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2336 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Article in PDF (280 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed787    
    Printed22    
    Emailed0    
    PDF Downloaded75    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
REPLY
Year : 2015  |  Volume : 47  |  Issue : 1  |  Page : 125-126
 

Reply



Date of Web Publication30-Jan-2015

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions



How to cite this article:
. Reply. Indian J Pharmacol 2015;47:125-6

How to cite this URL:
. Reply. Indian J Pharmacol [serial online] 2015 [cited 2019 Dec 9];47:125-6. Available from: http://www.ijp-online.com/text.asp?2015/47/1/125/150381


Sir,

I would like to respond to the queries raised by the author regarding our article published in the IJP titled "cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome." [1]

The concern raised by the author was regarding the finding from Amato et al. study indicating "effect of chlordiazepoxide being still inconclusive" with "great concern on the adverse effect." [2] Benzodiazepines, such as diazepam and chlordiazepoxide, despite their adverse effects, are still considered first line drugs to be used in alternative work schedules (AWS) worldwide as they can control the withdrawal effects very effectively compared to other available alternative medications. [3],[4] Amato et al. in their 1996 study could not establish definite conclusions regarding effectiveness and safety of benzodiazepines "because of the heterogeneity of the trials both in interventions and in the assessment of outcomes." Data on potential adverse effects were also "sparse and fragmented." [2]

Although research is ongoing to find better alternatives for the management of AWS, only some drugs, such as baclofen, a B gamma-aminobutyric acid agonist, have shown efficacy, at least, in uncomplicated AWS. [5] Many other drugs like topiramate, carbamazepine, clonidine, gabapentin, and calcium channel blockers including nifedipine have been tried in AWS management, but limited data exists on their effectiveness in managing AWS. [2] It is pertinent to note here that all adverse events and costs incurred in the management were considered for cost-effective analysis" in our study. [1]

 
  References Top

1.
Reddy VK, Girish K, Lakshmi P, Vijendra R, Kumar A, Harsha R. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Indian J Pharmacol 2014;46:372-7.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.
Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev 2011;CD008537.  Back to cited text no. 2
    
3.
National Institute for Health and Care Excellence. Acute alcohol withdrawal. Available from: http://www.pathways.nice.org.uk/pathways/alcohol-use-disorders/acute-alcohol-withdrawal.pdf. [Last cited on 2014 Aug 20].  Back to cited text no. 3
    
4.
Kumar CN, Andrade C, Murthy P. A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal. J Stud Alcohol Drugs 2009;70:467-74.  Back to cited text no. 4
    
5.
Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: A comparative study vs diazepam. Am J Med 2006;119:276.e13-8.  Back to cited text no. 5
    




 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow